A clustering approach to identify rare variants associated with hypertension by unknown
BMC ProceedingsThe Author(s) BMC Proceedings 2016, 10(Suppl 7):24DOI 10.1186/s12919-016-0022-0PROCEEDINGS Open AccessA clustering approach to identify rare
variants associated with hypertension
Rui Sun1, Qiao Deng2, Inchi Hu2, Benny Chung-Ying Zee1 and Maggie Haitian Wang1*From Genetic Analysis Workshop 19
Vienna, Austria. 24-26 August 2014Abstract
With the development of the next-generation sequencing technology, the influence of rare variants on complex
disease has gathered increasing attention. In this paper, we propose a clustering-based approach, the clustering
sum test, to test the effects of rare variants association by using the simulated data provided by the Genetic Analysis
Workshop 19 with an unbalanced case-control ratio. The control individuals are (a) clustered into several subgroups, (b)
statistics of the separate subcontrol groups as compared to the case group are calculated, and (c) a combined statistic
value is obtained based on a distance score. Collapsing of rare variants is used together with the proposed method. In
our results, comparing the same statistical test with and without clustering, the clustering strategy increases
the number of true positives identified in the top 100 markers by 17.24 %. Compared to the sequence kernel
association test, the proposed method is more robust in terms of replicated frequencies in the replicates data
sets. The results suggest that the clustering approach could improve the power of nonparametric tests and
that the clustering sum test has the potential to serve as a practical tool when dealing with rare variants
with unbalanced case-control data in genome-wide case-control studies.Background
Genome-wide association studies have successfully de-
tected a number of variants associated with complex
traits and provided valuable insights into the genetic eti-
ology of complex traits, but only a small portion of the
total heritability has been explained [1]. This current
situation leads to a question of the mysterious “missing
heritability.” One possible source of missing heritability
is the influence of rare variants under the common
disease rare variant hypothesis [2, 3]. With the develop-
ment of next-generation sequencing technology the
whole genome can be sequenced, which makes the ana-
lysis of rare variants possible. Previously proposed
methods to unveil associations of rare variants include
the weighted sum statistic [4], combined multivariate
and collapsing method [5], and the cohort allelic sums
test [6]. In this study, we proposed a novel approach,
namely, a clustering sum test (CST), to detect rare* Correspondence: maggiew@cuhk.edu.hk
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use of an individual’s quantitative phenotype informa-
tion. One of the most important advantages of CST
is the improvement in power to detect the effects of
rare causal variants, comparing them to the original
statistics without using additional parameters. We
apply the proposed method to the simulated data set
provided by the Genetic Analysis Workshop 19 (GAW19).
The optimal collapsing window size is evaluated and the
best result is compared to the sequence kernel association
test (SKAT).Methods
Data set
The GAW19 data set consists of the real whole genome
sequencing genotype data and 200 replicates of simu-
lated phenotypes, including the continuous systolic
(SBP) and diastolic blood pressure (DBP) and hyperten-
sion status. In this study, we use the genotypes on
chromosome 3, which include 48,510 single-nucleotide
polymorphisms (SNPs). Quality control is conductedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 The number of true positives identified under
collapsing window size 15
Top markers CST-χ2 χ2 Test SKAT
50 1.4 1.24 1.08
100 2.72 2.32 1.88
200 4.74 4.2 3.62
300 7.04 5.78 5.18
500 10.48 9.68 9.02
750 14.48 13.92 13.46
1000 18.62 18.74 17.6
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is more than 5 %, the minor allele frequency (MAF)
equals zero, or an inconsistent genotype format exists.
There are 1943 independent individuals and 42,825
SNPs that pass the quality control assessment with a
MAF of less than 1 %.
Association test for rare variants
Suppose a marker G has 3 genotypes AA, Aa, aa
coded as 0, 1, 2. Where a refers to the minor allele.
We want to analyze the association of G with the
binary phenotype Y, as well as with its continuous
phenotype information. In this study, a χ2 test is used
to measure this association.
Clustering and combination strategy
Step 1. K-means clustering for individuals’ classification
In this step, a K-means clustering method [7] is used
to cluster the control data into K groups, where K is an
optimal group number determined by cross-validation
[8]. Thus the K sets of control data have different average
levels of hypertension.
Step 2. Clustering sum test
Each control data set after clustering is matched with
the same case data set. The χ2 test statistic is then calcu-
lated. The clustering and the χ2 test statistic are then
combined with the weighted sum test.







Where, dk is the average phenotype distance between
the kth control group and the case group. D is the sum
of dk and Sk is the χ
2 test applied on the kth control and
case data sets.
Collapsing strategy
For all rare variants, SNPs within window size L are col-
lapsed as pseudo markers. Window sizes L are chosen as
1, 10, 15, 20, 25, 30, 50, where one refers to no collaps-
ing. CST is then applied to these pseudo markers and
the optimal collapsing window size is chosen.
Results
Selection of optimal collapsing window size
Rare variants on chromosome 3 are collapsed using dif-
ferent window sizes and the statistical test is conducted
to detect causal variants. A “pseudo marker” is 1 col-
lapsed marker and a corresponding “pseudo answer” isthe pseudo marker that contains at least 1 functional
causal variant. Table 1 shows the mean number of true
positives in top n pseudo markers in 50 replicates by
using 3 methods, namely, the CST based on the χ2 test,
the χ2 test, and SKAT [9], where n is set as 50, 100, 200,
300, 500, 750, 1000. Under the setting of chosen window
size 15, CST-χ2 outperforms the χ2 test and SKAT in dif-
ferent selection criteria settings. This is especially true
when the selection criteria is to be within the top 100
and 300; in those cases, the number of true positives
identified is 44.7 and 35.9 % higher, respectively, than
the numbers identified by SKAT.
The p value of each table count is estimated based on
a binomial distribution to describe the probability of
obtaining more than the observed number of answers
under the null hypothesis of no associations. Window
size 15 has been demonstrated to be the most significant
window size when the criteria setting is top 100 markers
(Fig. 1). When the same window size selection strategy
is applied to the χ2 test and SKAT, the optimal window
sizes are 15 and 10, respectively.
Comparison of the effectiveness of clustering versus
non-clustering
In this study, because CST is based on an χ2 test, the
main difference between CST and the χ2 test is the
clustering information. We use the results obtained
using optimal window size 15 to compare the perform-
ance of the CST approach to the χ2 test. The numbers
of pseudo answers identified in the top 100 and 300
markers are 2.72 and 7.04 using CST and 2.32 and
5.78using the χ2 test. In addition, we compare the gen-
eral performance across different window sizes, that is,
sizes other than 15. The significant levels of CST are
still stronger than the χ2 test in most cases (see Fig. 1).
In this respect, CST has a better performance and can
identify more causal markers than can the χ2 test. This
result indicates that involving more continuous pheno-
type information by clustering could increase the power
of nonparametric tests.
Fig. 1 Compare p values for the number of pseudo answers identified at different collapsing window sizes in the top 100 pseudo markers by
using Manhattan plot. Largest − Log(p value) indicates the best collapsing window. Optimal window sizes are pointed with arrows
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association test
In this part, we compare the number of causal markers
identified by CST and SKAT under their optimal window
sizes. Table 2 summarizes the information of the top 5 an-
swers that CST and SKAT identified and provides several
interesting findings.
Power and robustness of clustering sum test
In the top 2 pseudo answers detected, the replication
frequencies of CST are as high as 22 and 16 out of the
total 50 replicates, whereas they are 10 and 6 usingTable 2 Top 5 pseudo answers identified by CST and SKAT
Method Rank Rep freqa Gene Number of
SNPs identified
CST 1 22 MAP4 7
2 16 ZBTB38 1
3 9 SEMA3F 4
4 7 MLH1 6
5 7 SEMA3F 3
SKAT 1 10 ZBTB38 1
2 6 ARHGEF3 2
3 5 MAP4 1
4 5 FLNB 1
5 4 MUC13 1
aReplication frequency, replication times of being identified in 50 replicatesSKAT. In the top 5 pseudo answers, the replication fre-
quency is 96.3 % higher than it is for SKAT. These re-
sults show that CST is a more robust approach than
SKAT for identifying rare variants. This may be because
of the nonparametric nature of the CST, which could
weaken the influence of noise from different types of
underlying genetic architecture.
Validation and effect size of answers identified
Information on causal markers for hypertension in the
simulated data is provided by GAW19. The gene MAP4
shows the strongest effect among causal genes inSNP with the strongest effect Cumulative effect
Position SBP DBP SBP DBP
47912407 −20.621 −9.595 −114.19 −53.134
141164276 −0.007 −0.002 −0.007 −0.002
50225153 1.418 1.013 3.063 2.189
37092025 0 −0.449 0 −2.084
50222879 1.361 0.973 3.472 2.482
141164276 −0.007 −0.002 −0.007 −0.002
56835799 −0.067 −0.062 −0.127 −0.117
48040284 −20.808 −9.682 −20.808 −9.682
58134409 1.687 0.249 1.687 0.249
124646631 0 −2.178 0 −2.178
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tect MAP4 in the top 5 markers, although the detected
SNPs in MAP4 are not the same. MAP4 ranks first by
the CST, and this pseudo marker includes seven answer
SNPs with cumulative effects of −114.19 and −53.134 in
SBP and DBP, respectively. Cumulative effects in MAP4
identified by SKAT are −18.180 and −8.459 in SBP and
DBP. The cumulative effect is calculated by the sum of
SBP and DBP effects within the same collapsing window.
In addition, CST identifies the pseudo marker containing
more than three causal SNPs, whereas in the SKAT re-
sult, 4 of the top 5 pseudo answers contain only 1 causal
SNP. From this perspective, CST can detect causal
markers with the largest cumulative effect size in a ro-
bust manner whereas SKAT tends to detect markers
containing a single SNP with a different effect size rather
than with a large cumulative effect.
Little-overlapping markers identified
Surprisingly, the findings by the two methods show
very little overlap: only one marker is detected by both
methods at SNP position 141164276 in gene ZBTB38.
One gene, MAP4, could be detected in different re-
gions by both methods. Findings of these two genes
could further validate the effectiveness and accuracy of
CST: the top marker identified is supported to have the
strongest effect on hypertension and the second marker is
the only overlapped variant identified and ranked as the
topmost by SKAT. The small-overlapping pattern might
be a result of the difference between the theoretically
based hypothesis of the definition to measure the causal
relationship between markers and disease of interest. One
assumption behind collapsing is that the genetic probabil-
ity distribution is similar within the same collapsing re-
gion. CST could match the assumption to enlarge the
collapsed signals in the same effect direction. For SKAT, it
is a kernel regression to detect the effect in each region
and an inverse weight score is given to rare SNPs. SKAT
is more useful and sensitive for detecting SNPs in a region
with an opposite effect direction.
Discussion
Features of clustering sum test
In this paper, we propose a clustering-based test to
detect rare variants when continuous phenotypes are
available. There are three advantages of doing this:
First, the CST can make better use of phenotype infor-
mation, instead of just dichotomizing continuous phe-
notypes in a single case-control study. Second, when
the ratio of number of cases to controls is extreme, the
CST can balance the number of samples in each case-
control set by dividing the larger group into smaller
groups. Third, CST produces more robust results than
the other tests because of its nonparametric form. Allof the above findings suggest that CST has the poten-
tial to become a useful method in dealing with rare
variants in case-control studies and thus is worth fur-
ther investigation.
Issue in terms of genetic architecture
The CST has been shown to outperform SKAT with lar-
ger power when the collapsing region contains many
causal SNPs with the same effect direction. With the
collapsing strategy applied, the CST, as a burden test,
combines signals of rare variants within a certain region,
thus, signals of cumulative effects could be enlarged for
detecting whether the effects of causal variants are in
the same direction. SKAT is based on a multiple regres-
sion to directly measure the relationship between pheno-
types and multiple genetic variants in a region [9] and it
is able to capture effects in a region with different direc-
tions. SKAT tends to detect a rare variant region with a
single or a small number of causal markers with large ef-
fect. This phenomenon also suggests that extending the
scope of knowledge in different genetic architectures
could help when choosing an appropriate method in
genetic association studies.
Conclusions
Previous study on a similar version of GAW19 data sets
indicates that the false-positive rate is usually high, as
our results show in Table 1 [10]. The proposed CST ap-
proach has an attractive feature in that it increases
power by using continuous phenotypes combined with
categorical data tests for dichotomous phenotypes. It
could be generalized to apply to multiple phenotypes by
using different statistics to deal with unbalanced case-
control data for genetic association tests.
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